PMC:7600245 / 36050-37609
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T139 | 427-430 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T133 | 161-164 | Disease | denotes | NS3 | http://purl.obolibrary.org/obo/MONDO_0012371 |
| T134 | 436-439 | Disease | denotes | NS3 | http://purl.obolibrary.org/obo/MONDO_0012371 |
| T135 | 560-568 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T136 | 674-682 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T137 | 820-828 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T138 | 906-914 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T139 | 1165-1173 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T333 | 312-316 | http://purl.obolibrary.org/obo/CLO_0001185 | denotes | 2018 |
| T334 | 479-480 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T335 | 689-692 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T336 | 1140-1142 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
| T337 | 1370-1371 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T338 | 1415-1418 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T339 | 1543-1547 | http://purl.obolibrary.org/obo/CLO_0001360 | denotes | 4–12 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T550 | 96-110 | Chemical | denotes | peptidomimetic | http://purl.obolibrary.org/obo/CHEBI_63175 |
| T551 | 111-125 | Chemical | denotes | antiviral drug | http://purl.obolibrary.org/obo/CHEBI_36044 |
| T552 | 111-120 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T553 | 121-125 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T554 | 134-136 | Chemical | denotes | S4 | http://purl.obolibrary.org/obo/CHEBI_29401 |
| T555 | 148-157 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T556 | 405-414 | Chemical | denotes | aspartate | http://purl.obolibrary.org/obo/CHEBI_132943|http://purl.obolibrary.org/obo/CHEBI_29995|http://purl.obolibrary.org/obo/CHEBI_72314 |
| T559 | 582-601 | Chemical | denotes | protease inhibitors | http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258 |
| T561 | 591-601 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T562 | 760-779 | Chemical | denotes | protease inhibitors | http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258 |
| T564 | 769-779 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T565 | 948-967 | Chemical | denotes | protease inhibitors | http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258 |
| T567 | 957-967 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T568 | 1023-1032 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
| T569 | 1118-1121 | Chemical | denotes | INF | http://purl.obolibrary.org/obo/CHEBI_52999 |
| T570 | 1206-1215 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
| T571 | 1222-1231 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T572 | 1445-1454 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T265 | 0-4 | Sentence | denotes | 3.4. |
| T266 | 5-25 | Sentence | denotes | Danoprevir/Ritonavir |
| T267 | 26-138 | Sentence | denotes | Danoprevir (Ganovo) is an orally bioavailable 15-membered macrocyclic peptidomimetic antiviral drug (Figure S4). |
| T268 | 139-221 | Sentence | denotes | It is an inhibitor of NS3/4A HCV protease, an important processing enzyme complex. |
| T269 | 222-283 | Sentence | denotes | It inhibits the protease with an IC50 value of 0.29 nM [112]. |
| T270 | 284-347 | Sentence | denotes | It was approved in China in 2018 to treat chronic HCV patients. |
| T271 | 348-431 | Sentence | denotes | At higher concentrations, it also appears to inhibit the aspartate protease of HIV. |
| T272 | 432-571 | Sentence | denotes | The NS3/4A protease of HCV is claimed to share a certain level of structural and/or functional similarity to the protease(s) of SARS-CoV-2. |
| T273 | 572-683 | Sentence | denotes | Thus, HCV protease inhibitors, including danoprevir, have been proposed as potential therapeutics for COVID-19. |
| T274 | 684-980 | Sentence | denotes | This has also been supported by computational work which indicated that HCV protease inhibitors have high binding affinity to 3CLpro of SARS-CoV-2 [113] and by in vitro and clinical studies which showed that patients with SARS-CoV or MERS-CoV may benefit from HCV protease inhibitors [88,90,114]. |
| T275 | 981-1183 | Sentence | denotes | Currently, danoprevir in combination with ritonavir, is being evaluated in two clinical trials (NCT04345276; n = 10) and (with nebulized INF; NCT04291729; n = 11) for the treatment of COVID-19 patients. |
| T276 | 1184-1360 | Sentence | denotes | As mentioned earlier, ritonavir is an antiviral and pharmacokinetic booster that extends the systemic exposure of patients to potential therapeutic concentration of danoprevir. |
| T277 | 1361-1559 | Sentence | denotes | In fact, a recent clinical study results under review has indicated that danoprevir/ritonavir combination alleviated the symptoms in COVID-patients and accelerated their recovery in 4–12 days [115]. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1079 | 5-25 | Chemical | denotes | Danoprevir/Ritonavir | |
| 1101 | 338-346 | Species | denotes | patients | Tax:9606 |
| 1102 | 560-570 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 1103 | 820-830 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 1104 | 892-900 | Species | denotes | patients | Tax:9606 |
| 1105 | 906-914 | Species | denotes | SARS-CoV | Tax:694009 |
| 1106 | 918-926 | Species | denotes | MERS-CoV | Tax:1335626 |
| 1107 | 1174-1182 | Species | denotes | patients | Tax:9606 |
| 1108 | 1298-1306 | Species | denotes | patients | Tax:9606 |
| 1109 | 1500-1508 | Species | denotes | patients | Tax:9606 |
| 1110 | 26-36 | Chemical | denotes | Danoprevir | MESH:C553752 |
| 1111 | 38-44 | Chemical | denotes | Ganovo | |
| 1112 | 613-623 | Chemical | denotes | danoprevir | MESH:C553752 |
| 1113 | 992-1002 | Chemical | denotes | danoprevir | MESH:C553752 |
| 1114 | 1023-1032 | Chemical | denotes | ritonavir | MESH:D019438 |
| 1115 | 1206-1215 | Chemical | denotes | ritonavir | MESH:D019438 |
| 1116 | 1349-1359 | Chemical | denotes | danoprevir | MESH:C553752 |
| 1117 | 1434-1444 | Chemical | denotes | danoprevir | MESH:C553752 |
| 1118 | 1445-1454 | Chemical | denotes | ritonavir | MESH:D019438 |
| 1119 | 674-682 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1120 | 1165-1173 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1121 | 1494-1499 | Disease | denotes | COVID | MESH:C000657245 |